Obstructive sleep apnea is one of the few conditions where a GLP-1 drug has been tested against the thing itself rather than against the weight underneath it. SURMOUNT-OSA randomized adults with moderate-to-severe apnea and obesity to tirzepatide at the maximum tolerated dose of 10 or 15 mg, or placebo, for 52 weeks, and measured the apnea–hypopnea index directly [1]. If you are weighing one seller’s tirzepatide against another’s, this is the trial behind the molecule.
Two trials, two populations
The published work is two phase 3 trials, not one, and the split matters. Trial 1 enrolled participants not receiving positive airway pressure at baseline; trial 2 enrolled those who were. Mean baseline AHI was 51.5 events an hour in trial 1 and 49.5 in trial 2, with mean BMI of 39.1 and 38.7. These were people with severe apnea and substantial obesity, not a general population.
In trial 1, the mean change in AHI at week 52 was −25.3 events an hour (95% CI −29.3 to −21.2) with tirzepatide and −5.3 (95% CI −9.4 to −1.1) with placebo, a treatment difference of −20.0 events an hour (95% CI −25.8 to −14.2). In trial 2, the change was −29.3 against −5.5, a difference of −23.8 events an hour (95% CI −29.6 to −17.9). Both results were significant at P < 0.001.
What twenty events an hour means
Severity thresholds for apnea are conventionally set at 5, 15 and 30 events an hour. A participant starting at 51.5 and falling by 25 is moving from severe to moderate, not to nothing. The trial did not show that the drug resolves apnea; it showed a large reduction in a population with a great deal of it to lose. Hypoxic burden, high-sensitivity CRP, systolic blood pressure and patient-reported sleep measures all improved as well.
What it does not settle
Fifty-two weeks is one year, and apnea is a chronic condition. The trial does not describe what happens to AHI when the drug stops, which is the same open question that follows weight regain after discontinuation. The most frequently reported adverse events were gastrointestinal and mostly mild to moderate, which matches what the titration literature reports elsewhere. And the trial was funded by the manufacturer, as most trials of these drugs are.
A practical note for anyone buying: a seller pricing tirzepatide for weight loss is selling the same molecule, but an apnea indication is a clinical decision rather than a product tier. Nothing in a seller’s published disclosures speaks to it.